New study aimed at relieving hot flushes and night sweats experienced by women after breast cancer
Researchers in the Monash Women’s Health Research Program are conducting a study to evaluate a potential new treatment aimed at relieving hot flushes and night sweats in women diagnosed with breast cancer who are taking hormone-blocking therapy (either tamoxifen or an aromatase inhibitor).
While clinical trials have found hormone-blocking therapy can significantly reduce the risk of breast cancer coming back (recurring), many women experience menopausal-like symptoms when taking hormone-blocking therapy. While these side effects are mild for many women or lessen over time, some women experience significant symptoms which can be difficult to cope with.
The study will determine whether QUE 122 (a small molecule which was found to lessen hot flushes and night sweats in an earlier study) is effective in reducing night sweats and hot flushes in women affected by breast cancer being treated with hormone-blocking therapy.
You may be eligible to participate if you are:
- aged 18 to 70 years
- have been taking tamoxifen or an aromatase inhibitor i.e. anastrozole (Arimidex), letrozole (Femara) or exemestane (Aromasin) for at least 1 month
- are experiencing 7 or more hot flushes/night sweats each day.
This study is taking place at sites in Melbourne, Sydney, Adelaide and Perth.
If you are interested in participating or would like further information, please email email@example.com or call Corallee on +61 3 9903 0836.
More information about the study is also available on the Women’s Health Research Program’s website.
For information about hormone-blocking therapy, including how the drugs work, why they are beneficial and tips/strategies to help manage side effects, download BCNA’s Hormone therapy and breast cancer booklet on bcna.org.au.